Analystreport

Regeneron (NASDAQ: REGN) had its price target lowered by analysts at Morgan Stanley from $400.00 to $370.00. They now have an "equal weight" rating on the stock.

Regeneron Pharmaceuticals, Inc.  (REGN) 
Last regeneron pharmaceuticals, inc. earnings: 2/6 06:30 am Check Earnings Report
US:NASDAQ Investor Relations: investor.regeneron.com